The cannabinoid CP55,940 prolongs survival and improves locomotor activity in Drosophila melanogaster against paraquat: Implications in Parkinson's disease

Neuroscience Research

Volumn 61, Issue 4, 2008, Pages 404-411

  Jimenez Del Rio, M ^a   Daza Restrepo, A ^a   Velez Pardo, C ^a  

^a Neurosciences Research Program   (Colombia)

Author keywords

Cannabinoids; Drosophila melanogaster; Neuroprotection; Oxidative stress; Paraquat; Rescue

Indexed keywords

ALPHA TOCOPHEROL; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; GLUCOSE; PARAQUAT; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; CLIMBING; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DROSOPHILA MELANOGASTER; DRUG EFFICACY; ENZYME INHIBITION; FEMALE; FOOD INTAKE; HIGH RISK POPULATION; LOCOMOTION; MOTOR DYSFUNCTION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARAQUAT POISONING; PARKINSON DISEASE; PRIORITY JOURNAL; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; SURVIVAL RATE; SURVIVAL TIME;

ANIMALS; ANTHRACENES; ANTIOXIDANTS; BEHAVIOR, ANIMAL; CYCLOHEXANOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DROSOPHILA MELANOGASTER; DRUG INTERACTIONS; ENZYME INHIBITORS; FEEDING BEHAVIOR; FEMALE; GLUCOSE; HERBICIDES; IMMUNOSUPPRESSIVE AGENTS; MALE; MOTOR ACTIVITY; PARAQUAT; SURVIVAL ANALYSIS; TIME FACTORS; TOCOPHEROLS;

EID: 46149095463     PISSN: 01680102     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neures.2008.04.011     Document Type: Article

References (55)

1. Ashton J.C., Friberg D., Darlington C.L., and Smith P.F. Expression of the cannabinoid CB2 receptor in the rat cerebellum: an immunohistochemical study. Neurosci. Lett. 396 (2006) 113-116
2. Ballard P.A., Tetrud J.W., and Langston J.W. Permanent human Parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology 35 (1985) 949-956
3. Biglan K.M., and Ravina B. Neuroprotection in Parkinson's disease: an elusive goal. Semin. Neurol. 27 (2007) 106-112
4. Bonilla E., Medina-Leendertz S., Villalobos V., Molero L., and Bohórquez A. Paraquat-induced oxidative stress in Drosophila melanogaster: effects of melatonin, glutathione, serotonin, minocycline, lipoic acid and ascorbic acid. Neurochem. Res. 31 (2006) 1425-1432
5. Bove J., Prou D., Perier C., and Przedborski S. Toxin-induced models of Parkinson's disease. NeuroRx. 2 (2005) 484-894
6. Cha G.H., Kim S., Park J., Lee E., Kim M., Lee S.B., Kim J.M., Chung J., and Cho K.S. Parkin negatively regulates JNK pathway in the dopaminergic neurons of Drosophila. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 10345-10350
7. Chaudhuri A., Bowling K., Funderburk C., Lawal H., Inamdar A., Wang Z., and O'Donnell J.M. Interaction of genetic and environmental factors in a Drosophila Parkinsonism model. J. Neurosci. 27 (2007) 2457-2467
8. Chen Y., and Buck J. Cannabinoids protect cells from oxidative cell death: a receptor-independent mechanism. J. Pharmacol. Exp. Ther. 293 (2000) 807-812
9. Coulom H., and Birman S. Chronic exposure to rotenone models sporadic Parkinson's disease in Drosophila melanogaster. J. Neurosci. 24 (2004) 10993-10998
10. De Jesús M.L., Sallés J., Meana J.J., and Callado L.F. Characterization of CB1 cannabinoid receptor immunoreactivity in postmortem human brain homogenates. Neuroscience 140 (2006) 635-643
11. Demuth D.G., and Molleman A. Cannabinoid signalling. Life Sci. 78 (2006) 549-563
12. Dinis-Oliveira R.J., Remiao F., Carmo H., Duarte J.A., Navarro A.S., Bastos M.L., and Carvalho F. Paraquat exposure as an etiological factor of Parkinson's disease. Neurotoxicology 27 (2006) 1110-1122
13. Elbaz A., and Tranchant C. Epidemiologic studies of environmental exposures in Parkinson's disease. J. Neurol. Sci. 262 1/2 (2007) 37-44
14. Elphick M.R., and Egertová M. The phylogenetic distribution and evolutionary origins of endocannabinoid signalling. Handb. Exp. Pharmacol. 168 (2005) 283-297
15. Elsohly M.A., and Slade D. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci. 78 (2005) 539-548
16. Esposito E., Di Matteo V., and Di Giovanni G. Death in the substantia nigra: a motor tragedy. Exp. Rev. Neurother. 7 (2007) 677-697
17. Farrington J.A., Ebert M., Land E.J., and Fletcher K. Bipyridylium quaternary salts and related compounds. V. Pulse radiolysis studies of the reaction of paraquat radical with oxygen. Implications for the mode of action of bipyridyl herbicides. Biochim. Biophys. Acta 314 (1973) 372-381
18. Feany M.B., and Bender W.W. A Drosophila model of Parkinson's disease. Nature 404 (2000) 394-398
19. Fernández-Ruiz J., and Gonzáles S. Cannabinoid control of motor function at the basal ganglia. Handb. Exp. Pharmacol. 168 (2005) 479-507
20. Garcia-Arencibia M., Gonzalez S., de Lago E., Ramos J.A., Mechoulam R., and Fernandez-Ruiz J. Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties. Brain Res. 1134 (2007) 162-170
21. Hampson A.J., Grimaldi M., Axelrod J., and Wink D. Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 8268-8273
22. Hertzman C., Wiens M., Bowering D., Snow B., and Calne D. Parkinson's disease: a case-control study of occupational and environmental risk factors. Am. J. Ind. Med. 17 (1990) 349-355
23. Huang D., Ou B., and Prior R.L. The chemistry behind antioxidant capacity assays. J. Agric. Food Chem. 53 (2005) 1841-1856
24. Hurley M.J., Mash D.C., and Jenner P. Expression of cannabinoid CB1 receptor mRNA in basal ganglia of normal and Parkinsonian human brain. J. Neural Transm. 110 (2003) 1279-1288
25. Jiménez-Del-Rio M., and Velez-Pardo C. Paraquat induces apoptosis in human lymphocytes: protective and rescue effects of glucose, cannabinoids and insulin-like growth factor-1. Growth Factors 26 (2008) 49-60
26. Kim S.H., Won S.J., Mao X.O., Jin K., and Greenberg D.A. Involvement of protein kinase A in cannabinoid receptor-mediated protection from oxidative neuronal injury. J. Pharmacol. Exp. Ther. 313 (2005) 88-94
27. Lastres-Becker I., Molina-Holgado F., Ramos J.A., Mechoulam R., and Fernandez-Ruiz J. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiol. Dis. 19 (2005) 96-107
28. Lastres-Becker I., and Ruiz J.F. An overview of Parkinson's disease and the cannabinoid system and possible benefits of cannabinoid-based treatments. Curr. Med. Chem. 13 (2006) 3705-3718
29. Liou H.H., Tsai M.C., Chen C.J., Jeng J.S., Chang Y.C., Chen S.Y., and Chen R.C. Environmental risk factors and Parkinson's disease: a case-control study in Taiwan. Neurology 48 (1997) 1583-1588
30. Marsicano G., Moosmann B., Hermann H., Lutz B., and Behl C. Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1. J. Neurochem. 80 (2002) 448-456
31. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., and Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346 (1990) 561-564
32. Munro S., Thomas K.L., and Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365 (1993) 61-65
33. McPartland J., Di Marzo V., De Petrocellis L., Mercer A., and Glass M. Cannabinoid receptors are absent in insects. J. Comp. Neurol. 436 (2001) 423-429
34. Nagayama T., Sinor A.D., Simon R.P., Chen J., Graham S.H., Jin K., and Greenberg D.A. Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J. Neurosci. 19 (1999) 2987-2995
35. Niso-Santano M., Morán J.M., García-Rubio L., Gómez-Martín A., González-Polo R.A., Soler G., and Fuentes J.M. Low concentrations of paraquat induces early activation of extracellular signal-regulated kinase 1/2, protein kinase B, and c-Jun N-terminal kinase 1/2 pathways: role of c-Jun N-terminal kinase in paraquat-induced cell death. Toxicol. Sci. 92 (2006) 507-515
36. Onaivi E.S., Ishiguro H., Gong J.P., Patel S., Perchuk A., Meozzi P.A., et al. Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann. N.Y. Acad. Sci. 1074 (2006) 514-536
37. Padgett L.W. Recent developments in cannabinoid ligands. Life Sci. 77 (2005) 1767-1798
38. Pendleton R.G., Parvez F., Sayed M., and Hillman R. Effects of pharmacological agents upon a transgenic model of Parkinson's disease in Drosophila melanogaster. J. Pharmacol. Exp. Ther. 300 (2002) 91-96
39. Pendleton R.G., Rasheed A., Sardina T., Tully T., and Hillman R. Effects of tyrosine hydroxylase mutants on locomotor activity in Drosophila: a study in functional genomics. Behav. Genet. 32 (2002) 89-94
40. Peng J., Mao X.O., Stevenson F.F., Hsu M., and Andersen J.K. The herbicide paraquat induces dopaminergic nigral apoptosis through sustained activation of the JNK pathway. J. Biol. Chem. 279 (2004) 32626-32632
41. Peng J., Stevenson F.F., Doctrow S.R., and Andersen J.K. Superoxide dismutase/catalase mimetics are neuroprotective against selective paraquat-mediated dopaminergic neuron death in the substantial nigra: implications for Parkinson disease. J. Biol. Chem. 280 (2005) 29194-29198
42. Pineda-Trujillo N., Carvajal-Carmona L.G., Buriticá O., Moreno S., Uribe C., Pineda D., et al. A novel Cys212Tyr founder mutation in parkin and allelic heterogeneity of juvenile Parkinsonism in a population from North West Colombia. Neurosci. Lett. 298 (2001) 87-90
43. Pineda-Trujillo N., Apergi M., Moreno S., Arias W., Lesage S., Franco A., et al. A genetic cluster of early onset Parkinson's disease in a Colombian population. Am. J. Med. Genet. B Neuropsychiatr. Genet. 141 (2006) 885-889
44. Sang T.K., Chang H.Y., Lawless G.M., Ratnaparkhi A., Mee L., Ackerson L.C., et al. A Drosophila model of mutant human parkin-induced toxicity demonstrates selective loss of dopaminergic neurons and dependence on cellular dopamine. J. Neurosci. 27 (2007) 981-992
45. Sagredo O., García-Arencibia M., de Lago E., Finetti S., Decio A., and Fernández-Ruiz J. Cannabinoids and neuroprotection in basal ganglia disorders. Mol. Neurobiol. 36 (2007) 82-91
46. Smita K., Sushil, Kumar V., and Premendran J.S. Anandamide: an update. Fundam. Clin. Pharmacol. 21 (2007) 1-8
47. Tan E.K., and Skipper L.M. Pathogenic mutations in Parkinson disease. Hum. Mutat. 28 (2007) 641-653
48. Thakur G.A., Duclos Jr. R.I., and Makriyannis A. Natural cannabinoids: templates for drug discovery. Life Sci. 78 (2005) 454-466
49. Van Sickle M.D., Duncan M., Kingsley P.J., Mouihate A., Urbani P., Mackie K., et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310 (2005) 329-332
50. Velez-Pardo C., and Jimenez Del Rio M. Avoidance of Abeta[(25-35)]/(H(2)O(2))-induced apoptosis in lymphocytes by the cannabinoid agonists CP55,940 and JWH-015 via receptor-independent and PI3K-dependent mechanisms: role of NF-kappaB and p53. Med. Chem. 2 (2006) 471-479
51. Wang W., Shi L., Xie Y., Ma C., Li W., Su X., Huang S., Chen R., Zhu Z., Mao Z., Han Y., and Li M. SP600125, a new JNK inhibitor, protects dopaminergic neurons in the MPTP model of Parkinson's disease. Neurosci. Res. 48 (2004) 195-202
52. Wang D., Qian L., Xiong H., Liu J., Neckameyer W.S., Oldham S., Xia K., Wang J., Bodmer R., and Zhang Z. Antioxidants protect PINK1-dependent dopaminergic neurons in Drosophila. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 13520-13525
53. Wang C., Lu R., Ouyang X., Ho M.W., Chia W., Yu F., and Lim K.L. Drosophila overexpressing parkin R275W mutant exhibits dopaminergic neuron degeneration and mitochondrial abnormalities. J. Neurosci. 27 (2007) 8563-8570
54. Whitworth A.J., Wes P.D., and Pallanck L.J. Drosophila models pioneer a new approach to drug discovery for Parkinson's disease. Drug Discov. Today 11 (2006) 119-126
55. Yoshida Y., Saito Y., Jones L.S., and Shigeri Y. Chemical reactivities and physical effects in comparison between tocopherols and tocotrienols: physiological significance and prospects as antioxidants. J. Biosci. Bioeng. 104 (2007) 439-445